Screening (medicine)

Lore & Background

Screening in medicine is a strategy employed to detect unrecognized conditions or risk markers in individuals or populations who do not yet show symptoms or signs of the disease in question. The primary goal is to identify conditions that may eventually develop into disease, allowing for earlier intervention and management aimed at reducing mortality and suffering. However, not all screening tests have proven beneficial; potential adverse effects include overdiagnosis, misdiagnosis, and a false sense of security, and some tests may be inappropriately overused. A screening test, particularly for a low-incidence disease, must therefore possess good sensitivity alongside acceptable specificity. Screening interventions are not diagnostic and often yield significant rates of false positives and false negatives. Several types exist: universal or population-based screening tests all individuals in a defined category, such as all children of a certain age; case finding tests a smaller group based on risk factors, like a family history of hereditary disease; and targeted or stratified screening involves testing asymptomatic people at the population level because they have one or more risk factors. The World Health Organization’s 1968 Wilson and Jungner criteria established foundational principles for screening, which remain broadly applicable. These include that the condition should be an important health problem, there should be an available treatment and diagnostic facilities, a latent stage of the disease must exist, and the test should be acceptable to the population. The natural history of the disease must be understood, and there should be an agreed policy on whom to treat. The total cost of finding a case should be economically balanced, and case-finding should be a continuous process. In 2008, with genomic advances, the WHO synthesized emerging criteria, emphasizing that a screening programme should respond to a recognized need, have defined objectives and a target population, be supported by scientific evidence of effectiveness, and integrate education, testing, clinical services, and programme management. Quality assurance mechanisms must minimize risks, and the programme should ensure informed consent, confidentiality, respect for bodily autonomy, and equity of access. Overall benefits must outweigh harms, and economic considerations must be weighed alongs

Reader's Guide

Screening is a cornerstone of preventive medicine, but its application requires careful balancing of benefits and harms. These criteria emphasize that the condition must be an important health problem, a treatment must exist, and the natural history of the disease must be understood. Common screening programs include cancer screenings (e.g., Pap smear, mammography, colonoscopy), depression screening, and newborn hearing tests. However, screening is not diagnostic and can produce false positives and false negatives. In the US, recommendations are provided by the United States Preventive Services Task Force; in the UK, by the UK National Screening Committee. The social determinants of health have also become a focus of screening, as seen in programs established under the Affordable Care Act.

Did You Know?

• Screening tests can have significant rates of both false positive and false negative results.
• Common screening programs include Pap smear for cervical cancer, mammography for breast cancer, and colonoscopy for colorectal cancer.
• In the US, screening recommendations are provided by the United States Preventive Services Task Force.

Early Foundations and the Hirschfeld Legacy

For much of the twentieth century, the medical understanding of gender diversity remained largely absent from mainstream discourse. That changed in the 1920s when physician Magnus Hirschfeld undertook formal research into what we now recognize as gender dysphoria and the broader landscape of human sexuality. Hirschfeld's work was groundbreaking not only for its scientific rigor but for its explicit advocacy on behalf of communities that society had long marginalized. His studies offered a fundamentally new lens through which to view gender identity, gender expression, and sexual orientation, representing the first sustained intellectual challenge to rigid societal norms around gender. Hirschfeld also introduced the term "transvestite," a label that has since evolved into the modern understanding of "transgender." Tragically, his life's work was cut short during the Nazi era in Germany, a period in which transgender individuals faced arrest and were forcibly sent to concentration camps. Hirschfeld's legacy endures as a reminder that the medical recognition of transgender people is both a recent achievement and one that has been violently interrupted before.

Institutional Care and the Johns Hopkins Era

The mid-twentieth century saw the emergence of dedicated clinical infrastructure for transgender patients in the United States. In 1966, the Johns Hopkins Gender Identity Clinic opened its doors, becoming one of the first American institutions to offer comprehensive care to transgender individuals. The clinic's multidisciplinary approach encompassed hormone replacement therapy, surgical procedures, psychological counseling, and other forms of gender-affirming healthcare. A defining feature of the clinic's protocol was the "Real Life Test," a program requiring prospective surgical patients to live in their desired gender role for a prescribed period before undergoing gender-affirming surgery. This requirement reflected the era's cautious, gatekeeping approach to medical transition. However, the clinic's existence proved to be temporary. In 1979, Paul R. McHugh, the newly appointed director of psychiatry at Johns Hopkins, ordered the clinic shut down, abruptly ending a significant chapter in the institutional provision of transgender healthcare in the United States.

Shifting Diagnostic Frameworks

The medical community's classification of gender variance has undergone significant evolution, though the trajectory has been neither linear nor uncontested. For centuries, medicine treated gender variance as a pathology. The World Health Organization maintained this framing by listing gender dysphoria as a mental disorder in the International Classification of Diseases until 2018. The American Psychiatric Association's DSM-5 similarly included the condition, a term that had previously appeared as "transsexualism" and "gender identity disorder" in earlier revisions. A notable shift came with the ICD-11 update in 2018, which introduced "gender incongruence," defined as a marked and persistent mismatch between an individual's experienced gender and assigned sex, while noting that gender-variant behavior does not automatically constitute a medical diagnosis. Yet the distinction between "gender dysphoria" and "gender incongruence" remains ambiguous in much of the literature. Researchers continue to debate whether medicalizing gender variance causes harm or whether diagnostic categories serve as essential gateways to necessary care. Systematic reviews further underscore the urgent need for standardized data-collection methodologies to better understand how prevalent these experiences truly are within the general population.

Mental Health Disparities and the Path Forward

Transgender individuals face mental health disparities that are stark and well-documented. Across various countries, an estimated 32 to 50 percent of trans people have attempted suicide, a prevalence researchers attribute to victimization, bullying, violence, social and familial rejection, and systemic discrimination in public sectors. Beyond gender dysphoria, trans populations experience major depression and generalized anxiety at rates far exceeding those of the non-trans population. While gender-affirming care can positively impact mental health and alleviate certain symptoms, its psychological benefits are often constrained by ongoing minority stressors. In response, psychotherapy and mental health assessments play an important supporting role, particularly in ensuring informed consent before medical transition begins. Current trans healthcare protocols, however, discourage making psychotherapy a rigid prerequisite for affirmative care and explicitly reject approaches that attempt to alter a patient's identity or steer self-exploration in a prescribed direction. For transgender youth, professionals are urged to create respectful spaces for identity exploration without using that process to delay care or reframe trans identity as pathology, since such tactics mirror conversion practices known to cause significant harm.

Gallery